Business Description
Seelos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03832V3078
Description
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | -11.82 | |||||
| Debt-to-Equity | -0.36 | |||||
| Debt-to-EBITDA | 2.39 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 14.3 | |||||
| 3-Year EPS without NRI Growth Rate | 13.5 | |||||
| 3-Year FCF Growth Rate | 28.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -92.59 | |||||
| 12-1 Month Momentum % | -95.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.08 | |||||
| Quick Ratio | 0.08 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -75.3 | |||||
| Shareholder Yield % | -2682.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | Neg. Equity | |||||
| ROA % | 69.3 | |||||
| ROIC % | -130.57 | |||||
| ROC (Joel Greenblatt) % | 10601.01 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 2.42 | |||||
| EV-to-EBITDA | 2.39 | |||||
| EV-to-FCF | -0.77 | |||||
| Earnings Yield (Greenblatt) % | 41.32 | |||||
| FCF Yield % | -4227.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Seelos Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -445.322 | ||
| Beta | 0 | ||
| Volatility % | 119.15 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.005273 | ||
| 20-Day SMA (€) | 32 | ||
| 12-1 Month Momentum % | -95.27 | ||
| 52-Week Range (€) | 32 - 742.655904 | ||
| Shares Outstanding (Mil) | 0.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Seelos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Seelos Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Seelos Therapeutics Inc Frequently Asked Questions
What is Seelos Therapeutics Inc(FRA:NXE)'s stock price today?
The current price of FRA:NXE is €32.00. The 52 week high of FRA:NXE is €742.66 and 52 week low is €32.00.
When is next earnings date of Seelos Therapeutics Inc(FRA:NXE)?
The next earnings date of Seelos Therapeutics Inc(FRA:NXE) is 2024-11-28 Est..
Does Seelos Therapeutics Inc(FRA:NXE) pay dividends? If so, how much?
Seelos Therapeutics Inc(FRA:NXE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers